Organigram Holdings Inc. (TSE:OGI – Get Free Report)’s stock price fell 0.4% during trading on Monday . The stock traded as low as C$2.18 and last traded at C$2.26. 174,291 shares traded hands during mid-day trading, a decline of 22% from the average session volume of 223,412 shares. The stock had previously closed at C$2.27.
Analyst Ratings Changes
Several equities research analysts have weighed in on the stock. ATB Capital cut their target price on shares of Organigram from C$5.25 to C$3.50 in a report on Tuesday, December 17th. Canaccord Genuity Group dropped their price objective on Organigram from C$3.60 to C$3.15 and set a “speculative buy” rating on the stock in a research note on Monday, December 9th.
Read Our Latest Stock Analysis on Organigram
Organigram Stock Performance
Insider Buying and Selling
In related news, Senior Officer Paolo De Luca sold 12,014 shares of the stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of C$2.52, for a total transaction of C$30,275.28. 31.32% of the stock is currently owned by company insiders.
About Organigram
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O’ Buds, Monjour, Trailblazer, SHRED’ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Recommended Stories
- Five stocks we like better than Organigram
- 3 Best Fintech Stocks for a Portfolio Boost
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- What is a Dividend King?
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.